ADMA Gross Profit vs Income Tax Expense Analysis

ADMA Stock  USD 18.56  0.27  1.48%   
ADMA Biologics financial indicator trend analysis is way more than just evaluating ADMA Biologics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ADMA Biologics is a good investment. Please check the relationship between ADMA Biologics Gross Profit and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

Gross Profit vs Income Tax Expense

JavaScript chart by amCharts 3.21.1520162018202020222024-30M-20M-10M010M20M30M40M50M60M70M80M90M100M110M 02M4M6M8M10M12M14M16M18M20M
JavaScript chart by amCharts 3.21.15Gross Profittotal: 283.6MIncome Tax Expensetotal: 90.1M

Gross Profit vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ADMA Biologics Gross Profit account and Income Tax Expense. At this time, the significance of the direction appears to have very week relationship.
Gross ProfitIncome Tax ExpenseDiversified AwayGross ProfitIncome Tax ExpenseDiversified Away100%
The correlation between ADMA Biologics' Gross Profit and Income Tax Expense is 0.25. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of ADMA Biologics, assuming nothing else is changed. The correlation between historical values of ADMA Biologics' Gross Profit and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of ADMA Biologics are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Gross Profit i.e., ADMA Biologics' Gross Profit and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

0.25
Relationship DirectionPositive 
Relationship StrengthVery Weak

Gross Profit

Gross profit is a required income statement account that reflects total revenue of ADMA Biologics minus its cost of goods sold. It is profit before ADMA Biologics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Income Tax Expense

Most indicators from ADMA Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 203.48, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
 2022 2023 2024 2025 (projected)
Cost Of Revenue118.8M169.3M194.7M204.4M
Research Development3.6M3.3M3.0M4.4M

ADMA Biologics fundamental ratios Correlations

0.990.960.940.910.980.991.00.920.990.79-0.110.990.99-0.08-0.960.990.980.960.160.950.990.920.960.570.1
0.990.950.970.890.971.00.980.910.950.77-0.111.00.99-0.09-0.970.980.990.960.160.910.980.930.960.590.13
0.960.950.950.810.990.970.970.980.940.650.00.940.960.03-0.90.920.950.89-0.070.940.980.830.970.53-0.01
0.940.970.950.740.950.960.930.910.880.6-0.110.950.95-0.09-0.920.920.960.90.020.90.960.820.950.550.05
0.910.890.810.740.830.890.90.750.920.93-0.090.90.89-0.07-0.890.910.870.90.380.780.860.960.810.550.24
0.980.970.990.950.830.980.990.970.960.69-0.080.960.98-0.06-0.920.950.960.92-0.010.950.990.860.970.520.0
0.991.00.970.960.890.980.980.920.950.76-0.111.00.99-0.08-0.960.980.990.970.150.920.980.910.980.60.09
1.00.980.970.930.90.990.980.940.990.78-0.090.980.99-0.07-0.950.970.980.940.090.950.990.920.960.540.09
0.920.910.980.910.750.970.920.940.910.590.10.890.910.13-0.840.870.90.83-0.190.910.960.780.930.47-0.07
0.990.950.940.880.920.960.950.990.910.8-0.080.950.97-0.06-0.940.960.950.940.150.950.970.910.930.520.11
0.790.770.650.60.930.690.760.780.590.8-0.110.780.76-0.11-0.820.790.730.790.440.640.720.890.650.50.27
-0.11-0.110.0-0.11-0.09-0.08-0.11-0.090.1-0.08-0.11-0.12-0.151.00.19-0.13-0.15-0.14-0.32-0.14-0.07-0.11-0.11-0.01-0.06
0.991.00.940.950.90.961.00.980.890.950.78-0.120.99-0.1-0.970.990.990.980.220.90.970.930.960.620.12
0.990.990.960.950.890.980.990.990.910.970.76-0.150.99-0.13-0.970.990.990.970.170.950.980.910.970.580.12
-0.08-0.090.03-0.09-0.07-0.06-0.08-0.070.13-0.06-0.111.0-0.1-0.130.17-0.11-0.13-0.12-0.33-0.12-0.05-0.09-0.080.0-0.06
-0.96-0.97-0.9-0.92-0.89-0.92-0.96-0.95-0.84-0.94-0.820.19-0.97-0.970.17-0.97-0.96-0.96-0.27-0.9-0.94-0.92-0.92-0.6-0.17
0.990.980.920.920.910.950.980.970.870.960.79-0.130.990.99-0.11-0.970.980.990.30.920.950.920.960.630.14
0.980.990.950.960.870.960.990.980.90.950.73-0.150.990.99-0.13-0.960.980.970.170.940.970.880.980.60.14
0.960.960.890.90.90.920.970.940.830.940.79-0.140.980.97-0.12-0.960.990.970.370.890.920.910.940.670.14
0.160.16-0.070.020.38-0.010.150.09-0.190.150.44-0.320.220.17-0.33-0.270.30.170.370.020.010.340.090.380.42
0.950.910.940.90.780.950.920.950.910.950.64-0.140.90.95-0.12-0.90.920.940.890.020.950.780.940.490.07
0.990.980.980.960.860.990.980.990.960.970.72-0.070.970.98-0.05-0.940.950.970.920.010.950.890.960.510.05
0.920.930.830.820.960.860.910.920.780.910.89-0.110.930.91-0.09-0.920.920.880.910.340.780.890.830.530.27
0.960.960.970.950.810.970.980.960.930.930.65-0.110.960.97-0.08-0.920.960.980.940.090.940.960.830.590.08
0.570.590.530.550.550.520.60.540.470.520.5-0.010.620.580.0-0.60.630.60.670.380.490.510.530.590.02
0.10.13-0.010.050.240.00.090.09-0.070.110.27-0.060.120.12-0.06-0.170.140.140.140.420.070.050.270.080.02
Click cells to compare fundamentals

ADMA Biologics Account Relationship Matchups

ADMA Biologics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets207.7M276.3M348.5M329.2M378.6M397.5M
Short Long Term Debt Total97.7M102.9M154.4M141.4M162.6M170.8M
Total Current Liabilities19.9M30.4M39.3M49.8M57.3M60.1M
Net Debt41.7M51.8M67.9M90.1M103.6M108.8M
Cash55.9M51.1M86.5M51.4M59.1M62.0M
Common Stock Shares Outstanding86.1M139.6M197.9M224.0M257.6M270.5M
Liabilities And Stockholders Equity207.7M276.3M348.5M329.2M378.6M397.5M
Total Liab119.4M135.1M196.5M194.0M223.1M234.2M
Total Current Assets153.7M208.7M270.4M257.0M295.6M310.3M
Other Current Liab8.0M17.2M25.1M32.9M37.9M39.7M
Total Stockholder Equity88.2M141.2M152.0M135.2M155.5M163.3M
Cash And Short Term Investments55.9M51.1M86.5M51.4M59.1M29.7M
Common Stock Total Equity5.9K10.5K19.6K22.2K20.0K19.0K
Non Current Liabilities Total99.5M104.7M157.2M144.2M165.8M174.1M
Other Stockholder Equity428.7M553.3M630.0M641.4M737.7M774.5M
Common Stock10.5K19.6K22.2K23K20.7K29.8K
Retained Earnings(340.5M)(412.1M)(478.0M)(506.3M)(455.6M)(432.8M)
Property Plant And Equipment Net45.9M58.2M68.7M63.5M73.0M76.6M
Accounts Payable11.1M12.4M13.2M15.7M18.0M18.9M
Non Current Assets Total53.9M67.5M78.1M72.2M83.0M87.1M
Other Assets6.4M4.1M4.8M1.01.151.09
Net Receivables13.2M28.6M15.5M27.4M31.5M33.1M
Inventory81.5M124.7M163.3M172.9M198.8M208.8M
Other Current Assets6.1M4.3M10.2M5.3M6.1M6.4M
Property Plant And Equipment Gross45.9M50.9M58.3M90.2M103.7M108.9M
Non Currrent Assets Other2.1M4.1M4.8M4.7M5.4M5.6M
Other Liab2.4M2.2B2.4M3.7M4.2M4.0M
Net Tangible Assets19.5M82.3B141.2M152.0M174.8M166.0M
Long Term Debt93.0M94.9M142.8M130.6M150.2M157.7M
Retained Earnings Total Equity(264.7M)(340.5M)(412.1M)(478.0M)(430.2M)(408.7M)
Capital Surpluse290.9M428.7M553.3M630.0M724.5M760.7M
Capital Lease Obligations4.7M8.1M11.6M10.8M12.4M13.1M
Non Current Liabilities Other54.9K397.4K1.9M2.1M2.4M2.3M
Short Term Debt731.4K591.1K905K863.0K992.4K1.2M
Intangible Assets2.4M1.7M1.0M499K573.9K545.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
14
Earnings Share
0.27
Revenue Per Share
1.661
Quarterly Revenue Growth
0.781
Return On Assets
0.1989
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.